Accessibility Statement Skip Navigation
  • Resources
  • Data Privacy
  • Contact Us
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • All Multimedia

        • All Multimedia
        • All Photos
        • All Videos
    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Accessories
        • Computer Hardware
        • Computer Networks
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High-Tech Security
        • Internet Technology
        • Nanotechnology
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art, Culture & Design
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Projections or Forecasts
        • Financing Agreements
        • Insurance
        • Joint Ventures
        • Mutual Funds
        • Offerings
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing/marketing agreements
        • New Products & Services
        • Obituary
        • Outsourcing Businesses
        • Overseas Real Estate (Non-US)
        • Personnel Announcements
        • Residential Real Estate
        • Small-Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Accessories
        • Computer Electronics
        • Computer Hardware
        • Computer Networks
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Design Automation
        • Financial Technology
        • Mobile Devices/Apps
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Natural Gas Utilities
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Computer Accessories
        • Computer Networks
        • Mobile Devices/Apps
        • Telecommunications
        • Telecommunications Carriers & Services
        • Telecommunications Equipment
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wine & Spirits
        • Beverages
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art, Culture & Design
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infectious Disease Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental Products & Services
        • European Government
        • Natural Disasters
        • Not-for-Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Children-related news
        • Disabled Persons
        • Diversity, Equity & Inclusion
        • Hispanic-oriented news
        • LGBTQ+
        • Religion
        • Senior Citizens
        • Veterans
        • Women-Related news
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Request a Demo
    • Partnerships
    • Media Inquiries
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring Home
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us


    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • News Releases
      • Send a Release
      • Data Privacy
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • News Releases
      • Send a Release
      • Data Privacy
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • News Releases
      • Send a Release
      • Data Privacy
      • General Inquiries
      • Request a Demo
      • Partnerships
      • Media Inquiries
      • Editorial Bureaus
      • News Releases
      • Send a Release
      • Data Privacy
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • All Multimedia
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Prenetics Announces Third Quarter 2023 Financial Results


      News provided by

      Prenetics

      20 Nov, 2023, 19:30 CST

      Share this article

      Share this article


      HONG KONG, Nov. 20, 2023 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading genomics-driven health sciences company, today announced financial results for the third quarter ended September 30, 2023, along with recent business updates.

      Third Quarter 2023 Financial Highlights

      • Revenue from continuing operations of US$4.9 million
      • Adjusted EBITDA from continuing operations of US$(6.4) million
      • Cash and other short-term assets[1] of US$105.2 million as of September 30, 2023; with an additional $79.1 million of cash with Insighta, our 50/50 joint venture in early cancer detection with Professor Dennis Lo

      "During the third quarter, we made further progress on our transformation. The recent completion of the reverse stock split also addressed any uncertainty regarding our listing status. We believe there are significant opportunities with our consumer health and clinical oncology business units, and are making investments to address these significant opportunities. With the strong cash position and a strong team, we are confident in our pathway to deliver growth and value." said Danny Yeung, Chief Executive Officer and Co-Founder of Prenetics.

      Recent Highlights

      • Completion of reverse stock split at a ratio of 1-for-15 on November 14, 2023, to bring the Company into compliance with the minimum US$1.00 per share requirement for continued listing on NASDAQ
      • ACT Genomics launched ACTLiquid, a 500-gene comprehensive genomic profile "liquid" biopsy test
      • Cost reduction and restructuring progressed as planned, with business units CircleDNA and ACT Genomics expected to achieve EBITDA breakeven by the end of the year, which will be the first time in company history.
      • Insighta's 500-participants clinical trial for early cancer detection is in progress, and is expected to have full results for publication in the first half of 2024

      About Prenetics

      Prenetics (NASDAQ:PRE), a leading genomics-driven health sciences company, is revolutionizing prevention, early detection, and treatment. Our prevention arm, CircleDNA, uses whole exome sequencing to offer the world's most comprehensive consumer DNA test. Insighta, our US$200 million joint venture with renowned scientist Prof. Dennis Lo, underscores our unwavering commitment to saving lives through pioneering multi-cancer early detection technologies. Insighta plans to introduce Presight for lung and liver cancers in 2025, and to expand with Presight One for 10+ cancers in 2027. Lastly, ACT Genomics, our treatment unit, is the first Asia-based company to achieve FDA clearance for comprehensive genomic profiling of solid tumors via ACTOnco. Each of Prenetics' units synergistically enhances our global impact on health, truly embodying our commitment to 'enhancing life through science'. To learn more about Prenetics, please visit www.prenetics.com

      [1] Represents current assets, including cash and cash equivalents totaling US$71.3 million, financial assets at fair value through profit or loss of US$13.6 million, and trade receivables of US$4.5 million, amongst other accounting line items under current assets. Insighta is accounted for using equity method and is not consolidated in the results of Prenetics. 

      Forward-Looking Statements

      This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company's goals, targets, projections, outlooks, beliefs, expectations, strategy, plans, objectives of management for future operations of the Company, and growth opportunities are forward-looking statements. In some cases, forward-looking statements can be identified by words or phrases such as "may," "will," "expect," "anticipate," "target," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. Forward-looking statements are based upon estimates and forecasts and reflect the views, assumptions, expectations, and opinions of the Company, which involve inherent risks and uncertainties, therefore they should not be relied upon as being necessarily indicative of future results. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to: the Company's ability to further develop and grow its business, including new products and services; its ability to execute on its new business strategy in genomics, precision oncology, and specifically, early detection for cancer; the results of case control studies and/or clinical trials; and its ability to identify and execute on M&A opportunities, especially in precision oncology. In addition to the foregoing factors, you should also carefully consider the other risks and uncertainties described in the "Risk Factors" section of the Company's most recent registration statement and the prospectus therein, and the other documents filed by the Company from time to time with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

      Basis of Presentation

      Unaudited Financial Information and Non-IFRS Financial Measures has been provided in the financial statements tables included at the end of this press release. An explanation of these measures is also included below under the heading "Unaudited Financial Information and Non-IFRS Financial Measures."

      Unaudited Financial Information and Non-IFRS Financial Measures

      To supplement Prenetics' consolidated financial statements prepared in accordance with International Financial Reporting Standards ("IFRS"), the Company is providing non-IFRS measures, adjusted EBITDA from continuing operations, adjusted gross profit from continuing operations and adjusted (loss)/profit attributable to equity shareholders of Prenetics. These non-IFRS financial measures are not based on any standardized methodology prescribed by IFRS and are not necessarily comparable to similarly-titled measures presented by other companies. Management believes these non-IFRS financial measures are useful to investors in evaluating the Company's ongoing operating results and trends.

      Management is excluding from some or all of its non-IFRS results (1) Employee equity-settled share-based payment expenses, (2) depreciation and amortization, (3) finance income and exchange gain or loss, net, and (4) certain items that may not be indicative of our business, results of operations, or outlook, including but not limited to non-cash and/ or non-recurring items. These non-IFRS financial measures are limited in value because they exclude certain items that may have a material impact on the reported financial results. Management accounts for this limitation by analyzing results on an IFRS basis as well as a non-IFRS basis and also by providing IFRS measures in the Company's public disclosures.

      In addition, other companies, including companies in the same industry, may not use the same non-IFRS measures or may calculate these metrics in a different manner than management or may use other financial measures to evaluate their performance, all of which could reduce the usefulness of these non-IFRS measures as comparative measures. Because of these limitations, the Company's non-IFRS financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with IFRS. Investors are encouraged to review the non-IFRS reconciliations provided in the tables captioned "Reconciliation of loss from operations from continuing operations under IFRS and adjusted EBITDA from continuing operations (Non-IFRS)", "Reconciliation of gross profit from continuing operations under IFRS and adjusted gross profit from continuing operations (Non-IFRS)" and "Reconciliation of (loss)/profit attributable to equity shareholders of Prenetics under IFRS and adjusted (loss)/profit attributable to equity shareholders of Prenetics (Non-IFRS)" set forth at the end of this document.

      PRENETICS GLOBAL LIMITED

      Unaudited consolidated statements of financial position

      (Expressed in United States dollars unless otherwise indicated)








      September 30,


      June 30,


      December 31,


      2023


      2023


      2022


      $


      $


      $

      Assets






      Property, plant and equipment

      8,546,350


      10,031,570


      13,102,546

      Intangible assets

      13,674,683


      14,101,566


      14,785,875

      Goodwill

      33,800,276


      33,800,276


      33,800,276

      Interests in equity-accounted investees

      99,139,788


      559,193


      788,472

      Financial assets at fair value through profit or loss

      10,002,442


      -


      -

      Deferred tax assets

      27,715


      7,631


      243,449

      Deferred expenses

      5,335,829


      7,097,641


      6,307,834

      Other non-current assets

      700,710


      741,816


      1,292,462

      Non-current assets

      171,227,793


      66,339,693


      70,320,914







      Deferred expenses

      8,283,981


      8,588,431


      4,577,255

      Inventories

      3,290,184


      3,768,880


      4,534,072

      Trade receivables

      4,476,843


      5,636,969


      41,691,913

      Deposits, prepayments and other receivables

      4,145,935


      5,594,273


      6,889,114

      Amount due from a related company

      7,662


      -


      -

      Amount due from an equity-accounted investee

      137,161


      138,781


      -

      Financial assets at fair value through profit or loss

      13,593,201


      13,593,201


      17,537,608

      Short-term deposits

      16,000,000


      -


      19,920,160

      Cash and cash equivalents

      55,251,807


      177,179,297


      146,660,195

      Current assets

      105,186,774


      214,499,832


      241,810,317

      Total assets

      276,414,567


      280,839,525


      312,131,231







      Liabilities






      Deferred tax liabilities

      2,614,699


      2,694,720


      3,185,440

      Warrant liabilities

      895,400


      1,822,139


      3,574,885

      Lease liabilities

      3,062,803


      3,255,461


      3,763,230

      Other non-current liabilities

      717,461


      823,082


      949,701

      Non-current liabilities

      7,290,363


      8,595,402


      11,473,256







      Trade payables

      3,513,463


      4,226,392


      7,291,133

      Accrued expenses and other current liabilities

      8,347,371


      19,349,105


      15,611,421

      Contract liabilities

      4,504,343


      3,703,874


      5,674,290

      Lease liabilities

      2,194,574


      2,779,193


      2,882,933

      Liabilities for puttable financial instrument[2]

      13,230,021


      13,435,228


      17,138,905

      Tax payable

      8,550,228


      8,534,527


      8,596,433

      Current liabilities

      40,340,000


      52,028,319


      57,195,115

      Total liabilities

      47,630,363


      60,623,721


      68,668,371







      Equity






      Share capital[3]

      18,027


      15,791


      13,698

      Reserves

      224,417,177


      215,291,050


      237,050,429

      Total equity attributable to equity shareholders of the

        Company

      224,435,204


      215,306,841


      237,064,127

      Non-controlling interests

      4,349,000


      4,908,963


      6,398,733

      Total equity

      228,784,204


      220,215,804


      243,462,860

      Total equity and liabilities

      276,414,567


      280,839,525


      312,131,231

      PRENETICS GLOBAL LIMITED

      Unaudited consolidated statements of profit or loss and other comprehensive income

      (Expressed in United States dollars unless otherwise indicated)






      For the nine months ended


      September 30,


      September 30,


      2023


      2022


      $


      $




      (Restated)

      Continuing operations




      Revenue

      16,465,841


      12,586,661

      Direct costs

      (10,230,937)


      (7,892,047)

      Gross profit

      6,234,904


      4,694,614

      Other income and other net gain/(losses)

      3,725,604


      (744,886)

      Selling and distribution expenses[4]

      (6,334,964)


      (3,774,284)

      Research and development expenses[4]

      (10,158,212)


      (4,738,151)

      Restructuring costs[5]

      -


      (1,429,429)

      Administrative and other operating expenses[4]

      (33,910,726)


      (51,848,708)

      Loss from operations

      (40,443,394)


      (57,840,844)

      Fair value loss on financial assets at fair value through profit or loss

      (3,944,407)


      (1,674,184)

      Share-based payments on listing[6]

      -


      (89,546,601)

      Fair value loss on preference shares liabilities

      -


      (60,091,353)

      Fair value gain/(loss) on warrant liabilities

      2,679,485


      (3,301,827)

      Share of loss of equity-accounted investees

      (170,717)


      -

      Other finance costs

      (151,272)


      (3,993,550)

      Loss before taxation

      (42,030,305)


      (216,448,359)

      Income tax credit

      280,037


      3,355,516

      Loss from continuing operations

      (41,750,268)


      (213,092,843)

      Discontinued operation




      (Loss)/profit from discontinued operation, net of tax[7]

      (5,511,375)


      21,031,513

      Loss for the period

      (47,261,643)


      (192,061,330)





      Other comprehensive income for the period




      Item that may be reclassified subsequently to profit or loss:




        Exchange difference on translation of foreign operations

      677,474


      (7,602,604)

      Total comprehensive income for the period

      (46,584,169)


      (199,663,934)





      Loss attributable to:




      Equity shareholders of Prenetics

      (45,776,458)


      (192,061,275)

      Non-controlling interests

      (1,485,185)


      (55)


      (47,261,643)


      (192,061,330)





      Total comprehensive income attributable to:




      Equity shareholders of Prenetics

      (44,534,436)


      (199,663,879)

      Non-controlling interests

      (2,049,733)


      (55)


      (46,584,169)


      (199,663,934)





      Loss per share:




      Basic

      (0.28)


      (2.73)

      Diluted

      (0.28)


      (2.73)





      Loss per share - Continuing operations:




      Basic

      (0.24)


      (3.03)

      Diluted

      (0.24)


      (3.03)





      Weighted average number of common shares:




      Basic

      164,465,165


      70,371,679





      Diluted

      164,465,165


      70,371,679

      PRENETICS GLOBAL LIMITED

      Unaudited consolidated statements of profit or loss and other comprehensive income

      (Expressed in United States dollars unless otherwise indicated)








      For the three months ended


      September 30,


      June 30,


      September 30,


      2023


      2023


      2022


      $


      $


      $






      (Restated)

      Continuing operations






      Revenue

      4,865,522


      5,695,579


      4,295,343

      Direct costs

      (3,241,996)


      (3,559,119)


      (2,367,460)

      Gross profit

      1,623,526


      2,136,460


      1,927,883

      Other income and other net gain/(losses)

      1,096,199


      1,406,281


      (159,424)

      Selling and distribution expenses[4]

      (1,662,011)


      (2,171,640)


      (1,319,305)

      Research and development expenses[4]

      (3,980,620)


      (2,703,038)


      (796,688)

      Restructuring costs[5]

      -


      -


      (1,429,429)

      Administrative and other operating expenses[4]

      (10,752,382)


      (10,834,043)


      (15,240,243)

      Loss from operations

      (13,675,288)


      (12,165,980)


      (17,017,206)

      Fair value loss on financial assets at fair value through

        profit or loss

      -


      (3,944,407)


      (14,841)

      Fair value gain/(loss) on warrant liabilities

      926,739


      492,470


      (1,762,250)

      Share of gain/(loss) of equity-accounted investees

      54,567


      (112,533)


      -

      Other finance costs

      (42,914)


      (51,464)


      (110,548)

      Loss before taxation

      (12,736,896)


      (15,781,914)


      (18,904,845)

      Income tax credit

      11,210


      245,877


      1,384,285

      Loss from continuing operations

      (12,725,686)


      (15,536,037)


      (17,520,560)

      Discontinued operation






      (Loss)/profit from discontinued operation, net of tax[7]

      (1,354,767)


      (6,671,413)


      2,622,321

      Loss for the period

      (14,080,453)


      (22,207,450)


      (14,898,239)







      Other comprehensive income for the period






      Item that may be reclassified subsequently to profit or loss:






        Exchange difference on translation of foreign

          operations

      (480,209)


      1,794,185


      (2,826,668)

      Total comprehensive income for the period

      (14,560,662)


      (20,413,265)


      (17,724,907)







      Loss attributable to:






      Equity shareholders of Prenetics

      (13,570,455)


      (21,807,573)


      (14,898,231)

      Non-controlling interests

      (509,998)


      (399,877)


      (8)


      (14,080,453)


      (22,207,450)


      (14,898,239)







      Total comprehensive income attributable to:






      Equity shareholders of Prenetics

      (14,000,699)


      (20,037,819)


      (17,724,899)

      Non-controlling interests

      (559,963)


      (375,446)


      (8)


      (14,560,662)


      (20,413,265)


      (17,724,907)







      Loss per share:






      Basic

      (0.08)


      (0.14)


      (0.21)

      Diluted

      (0.08)


      (0.14)


      (0.21)







      Loss per share - Continuing operations:






      Basic

      (0.07)


      (0.10)


      (0.25)

      Diluted

      (0.07)


      (0.10)


      (0.25)







      Weighted average number of common shares:






      Basic

      176,151,516


      158,963,468


      70,371,679

      Diluted

      176,151,516


      158,963,468


      70,371,679

      PRENETICS GLOBAL LIMITED

      Unaudited Financial Information and Non-IFRS Financial Measures

      (Expressed in United States dollars unless otherwise indicated)





      Reconciliation of loss from operations from continuing operations under IFRS and adjusted EBITDA from continuing operations (Non-IFRS)






      For the nine months ended


      September 30,


      September 30,


      2023


      2022


      $


      $




      (Restated)

      Loss from operations from continuing operations under IFRS

      (40,443,394)


      (57,840,844)

      Employee equity-settled share-based payment expenses

      10,632,797


      22,597,827

      Depreciation and amortization

      5,820,321


      1,488,992

      Other strategic financing, transactional expense and non-recurring expenses

      6,064,443


      11,447,263

      Finance income, exchange gain or loss, net

      (3,573,445)


      967,707

      Adjusted EBITDA from continuing operations (Non-IFRS)

      (21,499,278)


      (21,339,055)





      Reconciliation of gross profit from continuing operations under IFRS and adjusted gross profit from continuing operations (Non-IFRS)






      For the nine months ended


      September 30,


      September 30,


      2023


      2022


      $


      $




      (Restated)

      Gross profit from continuing operations under IFRS

      6,234,904


      4,694,614

      Depreciation and amortization

      1,125,897


      85,309

      Adjusted gross profit from continuing operations (Non-IFRS)

      7,360,801


      4,779,923





      Reconciliation of loss attributable to equity shareholders of Prenetics under IFRS and adjusted (loss)/profit attributable to equity shareholders of Prenetics (Non-IFRS)






      For the nine months ended


      September 30,


      September 30,


      2023


      2022


      $


      $





      Loss attributable to equity shareholders of Prenetics under IFRS

      (45,776,458)


      (192,061,275)

      Employee equity-settled share-based payment expenses

      10,632,797


      28,338,511

      Other strategic financing, transactional expense and non-recurring expenses

      11,978,883


      10,941,228

      Share-based payment on listing                                                                              

      -


      89,546,601

      Fair value loss on preference shares liabilities

      -


      60,091,353

      Fair value (gain)/loss on warrant liabilities

      (2,679,485)


      3,301,827

      Fair value loss on financial assets at fair value through profit or loss

      3,944,407


      1,674,184

      Restructuring costs

      -


      27,669,598

      Adjusted (loss)/profit attributable to equity shareholders of Prenetics

        (Non-IFRS)

      (21,899,856)


      29,502,027

      PRENETICS GLOBAL LIMITED

      Unaudited Financial Information and Non-IFRS Financial Measures

      (Expressed in United States dollars unless otherwise indicated)







      Reconciliation of loss from operations from continuing operations under IFRS and adjusted EBITDA from continuing operations (Non-IFRS)








      For the three months ended


      September 30,


      June 30,


      September 30,


      2023


      2023


      2022


      $


      $


      $






      (Restated)

      Loss from operations from continuing operations

        under IFRS

      (13,675,288)


      (12,165,980)


      (17,017,207)

      Employee equity-settled share-based payment

        expenses

      4,394,952


      3,296,861


      4,637,222

      Depreciation and amortization

      1,885,127


      1,863,626


      564,942

      Other strategic financing, transactional expense and

        non-recurring expenses

      2,062,142


      3,077,902


      2,244,351

      Finance income, exchange gain or loss, net

      (1,103,499)


      (1,323,782)


      264,339

      Adjusted EBITDA from continuing operations

        (Non-IFRS)

      (6,436,566)


      (5,251,373)


      (9,306,353)







      Reconciliation of gross profit from continuing operations under IFRS and adjusted gross profit from continuing operations (Non-IFRS)








      For the three months ended


      September 30,


      June 30,


      September 30,


      2023


      2023


      2022


      $


      $


      $






      (Restated)

      Gross profit from continuing operations under IFRS

      1,623,526


      2,136,460


      1,927,883

      Depreciation and amortization

      405,923


      335,648


      33,523

      Adjusted gross profit from continuing operations

       (Non-IFRS)

      2,029,449


      2,472,108


      1,961,406







      Reconciliation of loss attributable to equity shareholders of Prenetics under IFRS and adjusted (loss)/profit attributable to equity shareholders of Prenetics (Non-IFRS)








      For the three months ended


      September 30,


      June 30,


      September 30,


      2023


      2023


      2022


      $


      $


      $







      Loss attributable to equity shareholders of Prenetics

        under IFRS

      (13,570,455)


      (21,807,573)


      (14,898,231)

      Employee equity-settled share-based payment

        expenses

      4,394,952


      3,113,656


      5,994,430

      Other strategic financing, transactional expense and

        non-recurring expenses

      2,061,178


      7,678,799


      391,354

      Fair value (gain)/loss on warrant liabilities

      (926,739)


      (492,470)


      1,762,250

      Fair value loss on financial assets at fair value through

        profit or loss

      -


      3,944,407


      14,841

      Restructuring costs

      -


      -


      27,669,598

      Adjusted (loss)/profit attributable to equity

        shareholders of Prenetics (Non-IFRS)

      (8,041,064)


      (7,563,181)


      20,934,242

      [2] In connection with the acquisition of ACT Genomics, the remaining shareholders of ACT Genomics - representing 25.61% of the fully diluted shareholding of ACT Genomics that Prenetics does not own - were granted put options which allow these remaining shareholders to put their remaining shares to Prenetics under certain conditions. The liabilities arising from such put option are recorded as liabilities for puttable financial instrument, and are valued at the present value of the exercise price of the put option.

      [3] Represents number of authorized and issued shares as follows:


      September 30,


      June 30,


      December 31,


      2023


      2023


      2022







      Number of authorized shares of $0.0001 each

      500,000,000


      500,000,000


      500,000,000







      Number of issued shares

      180,271,908


      157,905,434


      136,983,110

      [4] Includes equity-settled share-based payment expenses (excluding share-based payment on listing) from continuing operations as follows:


      For the nine months ended


      September 30,


      September 30,


      2023


      2022


      $


      $




      (Restated)

      Selling and distribution expenses

      100,561


      79,653

      Research and development expenses

      2,891,754


      1,658,775

      Administrative and other operating expenses

      7,576,865


      20,657,876

      Total equity-settled share-based payment expenses (excluding share-based

        payment on listing)

      10,569,180


      22,396,304


      For the three months ended


      September 30,


      June 30,


      September 30,


      2023


      2023


      2022


      $


      $


      $






      (Restated)

      Selling and distribution expenses

      (3,307)


      58,613


      48,229

      Research and development expenses

      1,530,858


      874,389


      412,928

      Administrative and other operating expenses

      2,845,319


      2,340,502


      4,168,498

      Total equity-settled share-based payment expenses

        (excluding share-based payment on listing)

      4,372,870


      3,273,504


      4,629,655

      [5] Includes restructuring costs from continuing operations as follows:


      For the nine months ended


      September 30,


      September 30,


      2023


      2022


      $


      $




      (Restated)

      Impairment of intangible assets

      -


      725,895

      Impairment of goodwill

      -


      703,534

      Total restructuring costs from continuing operations

      -


      1,429,429


      For the three months ended


      September 30,


      June 30,


      September 30,


      2023


      2023


      2022


      $


      $


      $






      (Restated)

      Impairment of intangible assets

      -


      -


      725,895

      Impairment of goodwill

      -


      -


      703,534

      Total restructuring costs from continuing operations

      -


      -


      1,429,429

      [6] The acquisition of the net assets of Artisan Acquisition Corp. ("Artisan") on May 18, 2022 does not meet the definition of a business under IFRS and has therefore been accounted for as a share-based payment. The excess of fair value of Prenetics shares issued over the fair value of Artisan's identifiable net assets acquired represents compensation for the service of a stock exchange listing for its shares and is expensed as incurred.

      [7] We ceased our COVID-19 testing business entirely in 2023 Q2. As a result, COVID-19 testing business is reported as a discontinued operation under IFRS 5 Non-current Assets Held for Sale and Discontinued Operations. In accordance with IFRS 5, the results of the discontinued operation have been presented separately from the continuing operations in the consolidated statements of profit or loss and other comprehensive income. The comparative information in the consolidated statements of profit or loss and other comprehensive income has also been re-presented to show the results of discontinued operation separately.

      SOURCE Prenetics

      Modal title

      Contact PR Newswire

      • General Inquiries
      • Request a Demo
      • Partnerships
      • Media Inquiries

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Become a Publishing Partner
      • Careers
      • Accessibility Statement
      • APAC – Simplified Chinese
      • APAC
      • APAC - Traditional Chinese
      • Arabic
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • United States
      • Vietnam

      My Services

      • All New Releases
      • Platform

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact Cision

      Products

      About

      My Services
      • All News Releases
      • Platform
      [email protected]
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      • Accessibility
      Copyright © 2026 Cision US Inc.